STOCK TITAN

Orchestra BioMed (OBIO) director awarded RSUs and options with tax-share withholding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Orchestra BioMed Holdings director David Pacitti reported compensation-related equity awards and a routine tax withholding. On June 23, 2026, he received 17,327 restricted stock units, each representing one future share of common stock, and a stock option for 21,277 shares at an exercise price of $4.04 per share. Both the RSUs and options vest on the one-year anniversary of the grant date, contingent on his continued service. On June 24, 2026, 3,784 shares were withheld by the company to cover tax obligations upon RSU vesting, with no shares sold in the market. Following these transactions, he directly holds 58,511 common shares and holds options for 21,277 additional shares.

Positive

  • None.

Negative

  • None.
Insider Pacitti David
Role null
Type Security Shares Price Value
Tax Withholding Common Stock 3,784 $0.00 --
Grant/Award Stock Option (Right to Buy) 21,277 $0.00 --
Grant/Award Common Stock, par value $0.0001 per share ("Common Stock") 17,327 $0.00 --
Holdings After Transaction: Common Stock — 58,511 shares (Direct, null); Stock Option (Right to Buy) — 21,277 shares (Direct, null); Common Stock, par value $0.0001 per share ("Common Stock") — 62,295 shares (Direct, null)
Footnotes (1)
  1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 23, 2026 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of RSUs. No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. The stock options will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.
RSU grant 17,327 units Restricted stock units granted June 23, 2026; 1 share per unit
Option grant size 21,277 shares Stock option covering common shares granted June 23, 2026
Option exercise price $4.04 per share Stock option exercise price for 21,277 underlying shares
Tax withholding shares 3,784 shares Shares withheld June 24, 2026 to satisfy RSU tax obligations
Common shares after transactions 58,511 shares Direct common stock holdings following tax withholding event
RSU vesting timing 1-year cliff RSUs vest one year after June 23, 2026, subject to service
Option expiration June 23, 2036 Expiration date of stock option granted June 23, 2026
restricted stock units financial
"Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Each RSU represents a contingent right to receive one share of Common Stock."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
tax withholding obligations financial
"Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of RSUs."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price": "4.0400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pacitti David

(Last)(First)(Middle)
C/O ORCHESTRA BIOMED HOLDINGS, INC.
150 UNION SQUARE DRIVE

(Street)
NEW HOPE PENNSYLVANIA 18938

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share ("Common Stock")06/23/2026A17,327(1)A$062,295D
Common Stock06/24/2026F(2)3,784D$058,511D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.0406/23/2026A21,277 (3)06/23/2036Common Stock21,277$021,277D
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") awarded to the Reporting Person on June 23, 2026 (the "Grant Date"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.
2. Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of RSUs. No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.
3. The stock options will vest on the one year anniversary of the Grant Date, subject to the Reporting Person's continuous service through such date.
/s/ Andrew Taylor, Attorney-in-Fact06/25/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did OBIO director David Pacitti report on this Form 4?

David Pacitti reported equity compensation grants and a tax-related share withholding. He received 17,327 restricted stock units and a stock option for 21,277 shares, and 3,784 shares were withheld to satisfy tax obligations related to RSU vesting, with no market sales involved.

How many Orchestra BioMed (OBIO) RSUs were granted to David Pacitti and when do they vest?

Pacitti was granted 17,327 restricted stock units on June 23, 2026. Each RSU converts into one share of common stock, vesting on the one-year anniversary of the grant date, subject to his continuous service with Orchestra BioMed through that vesting date.

What stock options did OBIO grant to David Pacitti and at what exercise price?

Orchestra BioMed granted Pacitti a stock option covering 21,277 shares of common stock at a $4.04 exercise price. The option was granted on June 23, 2026 and will fully vest one year after the grant date, contingent on his continued service with the company.

Why were 3,784 OBIO shares disposed of in David Pacitti’s Form 4?

The 3,784-share disposition reflects shares withheld by Orchestra BioMed to cover tax withholding obligations upon RSU vesting. According to the disclosure, no shares were sold in the open market; the shares were retained by the issuer solely for tax payment purposes.

How many Orchestra BioMed (OBIO) shares does David Pacitti own after these transactions?

After the reported transactions, Pacitti directly owns 58,511 shares of Orchestra BioMed common stock. In addition, he holds a stock option for 21,277 shares that will vest on the one-year anniversary of the June 23, 2026 grant date, assuming continued service.

Are the OBIO insider transactions by David Pacitti open-market buys or sales?

The filing shows no open-market purchases or sales by Pacitti. The acquisitions are equity compensation grants of RSUs and options, while the disposition is a tax withholding event where 3,784 shares were retained by the company to satisfy tax obligations on RSU vesting.